Antihyperlipidemics & Lipid Management Practice Test 2026 – The Complete Guide to Mastering Lipid Management!

In the management of high cholesterol, when patients can’t tolerate statins, clinicians look for non-statin therapies to lower LDL-C. Inclisiran fits here because it’s a PCSK9 pathway–targeting treatment delivered as a small interfering RNA. By silencing PCSK9 production in the liver, more LDL receptors stay active, so the liver clears more LDL from the blood, typically reducing LDL-C by about half. It’s approved for adults with primary hyperlipidemia or mixed dyslipidemia and is positioned as an option for statin-intolerant patients due to its mechanism and relatively convenient dosing (a few initial injections, then every six months). That’s why the statement is correct: inclisiran is listed as a possible option for statin-intolerant patients. It’s not a first-line statin substitute, and its use isn’t limited to diabetes.